Sellas Life Sciences Group Inc (SLS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.60B
Last updated: Nov 17, 2026 at 11:06 AM ET
Sellas Life Sciences Group Inc (SLS) Competitors
The companies most similar to Sellas Life Sciences Group are Celldex Therapeutics (CLDX), Maravai Lifesciences Holdings (MRVI) and Structure Therapeutics Inc. American Depositary Shares (GPCR). By market cap, Sellas Life Sciences Group ranks 6th of the 13 companies on this page; Beam Therapeutics (BEAM) is the largest at $2.36B.
Peer Comparison
SLS's revenue growth of -82.5% is below the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Sellas Life Sciences Group (SLS) | $1.60B | N/A | N/A | 0.0% | N/A | -82.5% | 0.00% |
| Celldex Therapeutics Inc (CLDX) | $2.26B | N/A | N/A | 0.0% | N/A | -97.0% | 0.00% |
| Maravai Lifesciences Holdings Inc (MRVI) | $1.96B | N/A | 5.2x | -30.8% | -28.3% | 10.1% | 0.00% |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | $1.43B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Silence Therapeutics PLC (SLN) | $1.23B | N/A | 882.5x | 0.0% | N/A | 197.2% | 0.00% |
| Nuvation Bio Inc (NUVB) | $1.41B | N/A | 6.7x | -67.4% | -18.7% | 242.6% | 0.00% |
| Intellia Therapeutics Inc (NTLA) | $1.36B | N/A | 26.1x | 0.0% | -50.0% | -48.0% | 0.00% |
| Rigel Pharmaceuticals Inc (RIGL) | $837.18M | 14.2x | 2.8x | 106.6% | 16.7% | 16.5% | 0.00% |
| Sarepta Therapeutics Inc (SRPT) | $1.72B | N/A | 0.8x | -5.9% | -3.2% | -4.5% | 0.00% |
| Vor Biopharma Inc (VOR) | $1.19B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Tyra Biosciences Inc (TYRA) | $1.38B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Beam Therapeutics Inc (BEAM) | $2.36B | N/A | 15.0x | -73.9% | -29.7% | -96.8% | 0.00% |
| Zenas BioPharma, Inc. Common Stock (ZBIO) | $1.90B | N/A | 168.0x | 0.0% | -104.3% | -100.0% | 0.00% |
| Peer median | $1.42B | 14.2x | 10.8x | 0.0% | -28.3% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Sellas Life Sciences Group, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Celldex Therapeutics Inc (CLDX) | Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment... | CLDX competitors |
| Maravai Lifesciences Holdings Inc (MRVI) | Maravai LifeSciences Holdings, Inc., a life sciences company, offers products to enable the development of drug therapies, diagnostics, novel vaccines... | MRVI competitors |
| Structure Therapeutics Inc. American Depositary Shares (GPCR) | Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic... | GPCR competitors |
| Silence Therapeutics PLC (SLN) | Silence Therapeutics plc, a biotechnology company, is focused on the discovery and development of new ribonucleic acid (RNA) therapies in hematology... | SLN competitors |
| Nuvation Bio Inc (NUVB) | Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. | NUVB competitors |
| Intellia Therapeutics Inc (NTLA) | Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts. | NTLA competitors |
| Rigel Pharmaceuticals Inc (RIGL) | Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. | RIGL competitors |
| Sarepta Therapeutics Inc (SRPT) | Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy... | SRPT competitors |
| Vor Biopharma Inc (VOR) | Vor Biopharma, Inc., an early stage cell therapy company, develops hematopoietic stem cell (eHSC) therapies designed for cancer patients. | VOR competitors |
| Tyra Biosciences Inc (TYRA) | Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and improve outcomes... | TYRA competitors |
| Beam Therapeutics Inc (BEAM) | Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. | BEAM competitors |
| Zenas BioPharma, Inc. Common Stock (ZBIO) | Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based... | ZBIO competitors |
Frequently Asked Questions About SLS
Who are Sellas Life Sciences Group's main competitors?
The companies most similar to Sellas Life Sciences Group include Celldex Therapeutics (CLDX), Maravai Lifesciences Holdings (MRVI), Structure Therapeutics Inc. American Depositary Shares (GPCR), Silence Therapeutics (SLN) and Nuvation Bio (NUVB), listed from the closest match.
Who is Sellas Life Sciences Group's biggest competitor?
Beam Therapeutics (BEAM) is the largest of the similar companies at $2.36B; Celldex Therapeutics (CLDX) is the closest match by business profile, size, sector and industry.
How does SLS stock compare with its competitors?
SLS' net margin is 0.0% against a peer median of 0.0%.
Which of Sellas Life Sciences Group's competitors pays a higher dividend?
Sellas Life Sciences Group pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Sellas Life Sciences Group bigger than its competitors?
No. Sellas Life Sciences Group is 6th by market cap among the 13 companies on this page; the largest is Beam Therapeutics (BEAM) at $2.36B.
SLS pages: Overview, Earnings, Forecast, Financials, Competitors